GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Inventories, Other

XORTX Therapeutics (XORTX Therapeutics) Inventories, Other : $0.00 Mil (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. XORTX Therapeutics's other inventories for the quarter that ended in Sep. 2023 was $0.00 Mil.


XORTX Therapeutics Inventories, Other Historical Data

The historical data trend for XORTX Therapeutics's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Inventories, Other Chart

XORTX Therapeutics Annual Data
Trend Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22
Inventories, Other
Get a 7-Day Free Trial - - - - -

XORTX Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

XORTX Therapeutics Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


XORTX Therapeutics (XORTX Therapeutics) Business Description

Traded in Other Exchanges
Address
3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.